house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; house mark for a full line of biologics; house mark for a full line of biosimilars; house mark for a full line of pharmaceuticals; house mark for a full line of biologic, biosimilar, and pharmaceutical products; biologic, biosimilar, and pharmaceutical preparations for the treatment of bone disease; biologic, biosimilar, and pharmaceutical preparations for use in the treatment of oncological and metabolic diseases and disorders, and complications associated therewith; biologic, biosimilar, and pharmaceutical preparations for the treatment of diabetes; biologic, biosimilar, and pharmaceutical preparations for treatment and prevention of autoimmune diseases and autoimmune disorders; biologic, biosimilar, and pharmaceutical oncology preparations; anti-inflammatories; biologic, biosimilar, and pharmaceutical preparations for the treatment of immune system related diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for use in dermatology; biologic, biosimilar, and pharmaceutical preparations for use in rheumatology; biologic, biosimilar, and pharmaceutical preparations, namely, anti-tumor necrosis factor alpha (TNFa) receptor monoclonal antibody for the treatment of disease influenced by TNFa production; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment of immune and inflammatory diseases and disorders